Glenmark Pharmaceuticals launches Apremilast in India

25 Oct 2017 Evaluate

Glenmark Pharmaceuticals has launched Apremilast, the first advanced oral systemic treatment for Psoriasis in India. Apremilast, which is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of moderate to severe Psoriasis, will revolutionize the treatment of Psoriasis.

The company has launched Apremilast under the brand name Aprezo. It has received approval from DCGI for Apremilast after conducting clinical trials on the molecule as per the regulatory requirements.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).


Glenmark Pharma Share Price

1919.05 -46.70 (-2.38%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×